AI
Tuesday, August 20, 2019 6:01:15 PM
N2K, you forgot to address the CNS market that has been posited as shrinking.
Nah, I did not. Rather, I saved it for this point because it is argued that Elite's newest best selling drug is in a market said to be shrinking.
Sorry, it took me a moment to stop laughing...because the reality is Elite is increasing revenues through IR Adderall, a CNS drug. Moreover, it seems apparent they have jumped the hurdles thrown at them by the FDA for the ER CNS ANDA (ER Adderall?) with the GDUFA in December. So, what else can be argued against their success but a smaller or shrinking market. How predictable that line of BS was in arriving and how easy to discredit...with this...
It remains that Elite is increasing revenues into a market that suffers from greater demand than supply. Ergo, Elite is in a market of need; so it is increasing revenues and the future suggests the revenues are recurring and will continue to increase...Sounds pretty good for shareholders longer term.
Nah, I did not. Rather, I saved it for this point because it is argued that Elite's newest best selling drug is in a market said to be shrinking.
Sorry, it took me a moment to stop laughing...because the reality is Elite is increasing revenues through IR Adderall, a CNS drug. Moreover, it seems apparent they have jumped the hurdles thrown at them by the FDA for the ER CNS ANDA (ER Adderall?) with the GDUFA in December. So, what else can be argued against their success but a smaller or shrinking market. How predictable that line of BS was in arriving and how easy to discredit...with this...
It remains that Elite is increasing revenues into a market that suffers from greater demand than supply. Ergo, Elite is in a market of need; so it is increasing revenues and the future suggests the revenues are recurring and will continue to increase...Sounds pretty good for shareholders longer term.
